Need Support?
Microbiology billing runs on reflex logic generalist billers miss. Culture-to-sensitivity workflows, target-count-dependent molecular panel codes, and MolDX documentation each carry their own coverage rules; one missed linkage between a positive culture and its susceptibility panel can strip revenue before a claim reaches the payer. TransLabs’ microbiology-certified coders close those gaps: 98% clean claims, 27% faster A/R, measurable recovery inside 90 days.
Microbiology billing isn’t simple culture-and-code work. Reflex susceptibility rules, panel target-count thresholds, MolDX assessment requirements, and CLIA-tied testing create an environment where a correct claim gets denied; linked to the wrong parent code, diagnosis, or documentation. The loss isn’t one event; it’s a slow bleed across thousands of claims nobody’s watching.
Culture-to-Susceptibility Reflex Miscapture
Respiratory & GI Panel Target-Count Miscoding
Missing MolDX Documentation for Molecular Panels
Polymicrobial Culture Modifier Errors
CLIA Certificate Omission on High-Complexity Testing
Blood culture with isolation and identification (87040), urine culture quantitative colony count (87086), urine culture with isolation and presumptive identification (87088), throat/aerobic culture (87070), stool culture for Salmonella/Shigella (87045), wound and respiratory cultures, and definitive organism identification (87076–87077).
87070 and 87086/87088 are frequently denied together under NCCI column 1/column 2 edits when billed for different specimen sources on the same date; Modifier 59 is required to indicate the cultures came from genuinely separate, medically necessary specimens.
Susceptibility by disk diffusion (87181), microdilution or agar dilution (87186), minimum inhibitory concentration (MIC) studies, and susceptibility testing repeated per isolate when a specimen is polymicrobial.
Susceptibility codes are reflex-only and must be linked to a positive parent culture code on the claim or in the record; CMS guidance confirms 87186 may be billed once per isolate when a specimen yields multiple significant organisms, but the CLIA certificate number must appear on every claim since this is a high-complexity test category.
Fungal culture isolation with presumptive identification from skin, hair, or nail (87101) or other sources (87102), mycobacterial AFB smear and culture, definitive fungal identification, and susceptibility testing for antifungal agents.
Fungal and mycobacterial cultures often require extended incubation periods that generate a separate date-of-service claim from the original specimen accession; billing systems that don't track pending mycobacterial cultures separately routinely lose this revenue to timely-filing deadlines.
Respiratory virus panel by target count — 3–5 targets (87631), 6–12 targets (87632), 12–20 targets (87633) — gastrointestinal pathogen panels by target count (87505–87507), and molecular syndromic panels for infectious disease pathogen identification under MolDX policy.
Most Medicare MACs' MolDX local coverage determinations consider respiratory and GI panels above five targets not medically necessary outside specific high-risk clinical scenarios; billing 87632 or 87633 without documentation supporting the broader panel is one of the most heavily audited denial categories in molecular microbiology.
Rapid influenza antigen (87804), RSV antigen (87420), COVID-19 antigen (87426), group A strep antigen (87880), H. pylori stool antigen (87338), and C. difficile toxin immunoassay (87324).
Rapid antigen tests carry their own frequency and medical necessity edits distinct from the molecular versions of the same pathogen; billing an antigen and a molecular NAAT for the same organism on the same date without distinct clinical justification triggers duplicate-service denials.
Ova and parasite examination, direct smear (87177), concentration technique, permanent stained smear for intestinal parasites, and blood smear for malaria or other blood parasites (87207–87209).
Ordering patterns for O&P testing frequently request multiple specimens across different collection days; billing all specimens under a single date of service instead of the actual collection dates is a common cause of frequency-related denials.
Chlamydia trachomatis NAAT (87491), Neisseria gonorrhoeae NAAT (87591), combined CT/GC panel testing, trichomonas vaginalis NAAT (87661), and herpes simplex virus PCR (87529–87530).
Many commercial payers require age- or risk-based medical necessity documentation for combined STI panel testing, and claims billed without a supporting screening or symptomatic diagnosis code are a frequent denial trigger in outpatient and urgent care settings.
TransLabs’ specialized RCM services are built exclusively for labs, addressing the unique challenges that generalist billers miss. We provide end-to-end revenue cycle solutions designed specifically to turn laboratory complexity into profitability.
Complete payer enrollment, CLIA certification management, and network participation setup across all insurance carriers. TransLabs manages every credentialing detail so that your laboratory gets paid in-network from day one without any administrative delays.
Real-time insurance verification, benefits investigation, and prior auth completed before specimen processing begins. Confirming coverage upfront eliminates preventable denials and protects your lab from unexpected reimbursement failures.
Patient registration, appointment coordination, insurance verification, and customer service excellence managed by experienced laboratory billing professionals. A well-run front office reduces downstream billing errors and creates a better experience.
TransLabs provides expert RCM services to clinical laboratories in all 50 states, delivering the same exceptional results whether you’re a community hospital lab or a large reference facility. We bring specialized lab billing expertise to facilities nationwide, combining remote efficiency with hands-on partnership.
Each Medicare Administrative Contractor maintains its own LCD specifying which ICD-10 codes support coverage for cultures, susceptibility testing, and molecular pathogen panels. TransLabs maintains live LCD databases for every MAC and validates diagnosis code linkage on every microbiology claim before submission.
Molecular syndromic panels for infectious disease pathogen identification fall under MolDX policy, which frequently requires a Z-Code identifier and a completed technical assessment on file before a claim is payable. TransLabs tracks which of your molecular tests require MolDX registration and confirms documentation is current before claims go out.
Most MolDX local coverage determinations consider multiplex respiratory and gastrointestinal pathogen panels above five targets not medically necessary outside defined high-risk clinical scenarios. TransLabs validates target count against payer policy and clinical documentation before a broader panel claim is submitted.
Culture codes from different specimen sources billed on the same date, and susceptibility codes billed without their parent culture, are subject to National Correct Coding Initiative edits. TransLabs runs every microbiology claim through an NCCI edit check before it leaves our system, not after a denial arrives.
Antimicrobial susceptibility testing and many molecular assays are classified as high-complexity under CLIA, and claims are denied when the lab's CLIA certificate number is missing or doesn't match the required certificate type. TransLabs verifies CLIA certificate data on every applicable claim.
Labs meeting the applicable laboratory definition under PAMA carry mandatory private payer data reporting obligations, and microbiology test volumes are frequently part of that reporting base. TransLabs tracks these obligations and ensures reporting deadlines are met.
Multiplex respiratory and gastrointestinal pathogen panel overutilization has drawn sustained OIG and payer audit scrutiny in recent cycles. TransLabs builds compliance protocols specifically around current OIG focus areas to reduce your audit exposure before it becomes a problem.
Microbiology billing has its own reflex-testing framework, MolDX documentation requirements, panel target-count coverage rules, and CLIA certification structure. TransLabs was built for lab billing; coders stay in microbiology; not chemistry one week and molecular infectious disease the next.
Schedule a call with our microbiology billing specialist. We’ll review your culture-to-susceptibility linkage, molecular panel coverage, MolDX documentation, and A/R days.
Dedicated microbiology billing specialist assigned to your lab
Complimentary 12-month claims audit across Medicare, Medicaid, and commercial payers
Uncover your top 3 revenue leaks in reflex linkage, panel target counts, and MolDX documentation
Custom strategy tailored to your analyzer platform and LIS/billing software
Live in 24 hours with no contracts and no upfront fees
Pay only a percentage of what we collect for you